Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-smooth muscle actin (α-SMA) is a specialized actin isoform predominantly expressed in vascular and visceral smooth muscle cells, encoded by the ACTA2 gene. It is a globular structural protein that polymerizes to form filaments (microfilaments), forming a key component of the cytoskeleton and contractile apparatus in muscle cells. In non-muscle cells, notably myofibroblasts, α-SMA expression correlates with increased contractile activity important for wound healing, matrix remodeling, and fibrogenesis. α-SMA is a hallmark marker of myofibroblast activation and is used extensively in research and pathology as a biomarker for fibrosis and tissue repair processes. Mutations in ACTA2 underpin a range of vascular and fibrotic diseases. Although it plays crucial roles in cellular contractility and mechanotransduction, it is not a classical drug target such as a receptor, transporter, or enzyme, but rather serves as a structural marker and effector in disease-related cellular phenotypes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-smooth muscle actin (α-SMA).